Introduction IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of association
study of Innate lymphoid cells from TC-1 tumors, 1,3 and 7 days after a cisplatin treatment (or PBS as control) Overall design: study of ILCs from PBS or Cisplatin treated TC-1 tumors
Introduction IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of association
